Brand profile · Pharmaceutical Manufacturing

NeuClone

Sydney, New South Wales-based NeuClone operates in Pharmaceutical Manufacturing. Ownership is publicly held; it publishes at neuclone.com. It holds one address on record, all in Australia. The record counts 9 people. Tagged biosimilars, monoclonal antibodies and biosimilar antibody development in CHO cells. One Australian registration (ABN) is a confirmed match. It is listed alongside one similar brand, in Pharmaceutical Manufacturing.

neuclone.com LinkedIn

Profile live Public Company 1 entity ABN 1 office country
Registry verified · ABR
Counted staff
9
self-reported band not used
Founded
Not recorded
Legal entities
1
ABR
Office countries
1
1 address
Funding rounds
None on record
Company type
Public Company
self-reported
Use this profile Compare Your shortlist

Legal entity

1 brand → 1 confirmed entity

  • NEUCLONE PTY LTD

    ABN56123989659

    NSWHigh confidenceMatched on exact nameABR

Legal entities

NeuClone: 1 registry entityNeuClone is linked to 1 registry entity: NEUCLONE PTY LTD (ABN 56123989659, candidate).NeuCloneNEUCLONE PTY LTDABN 56123989659Candidate · High confidence
Show as table
NEUCLONE PTY LTDABN 56123989659
Confirmed matches0 of 1

A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.

Description

NeuClone is a clinical stage biopharmaceutical company exclusively developing and commercialising high quality biosimilar products. Led by a team of industry veterans, we are focused on creating a deep pipeline of high quality biosimilars at the scale and price to meet demand in both new and established markets globally. NeuClone is differentiated by our deep and unmatched pipeline, as well as our Right From the Start® approach where we continually confirm biosimilarity at the earliest stages and throughout development.

Specialties

All 5 specialties
  • biosimilars
  • monoclonal antibodies
  • biosimilar antibody development in CHO cells
  • therapeutic antibodies
  • biologics

Locations

Australiaprimary

Country footprint

Offices in 1 countryCountry footprint: 1 country, primary AU. Codes: AU.1 countryprimary AUAU
Show as table
Countries1
Primary countryAU

All codes: AU

Addresses

  • AU4 Cornwallis St; Sydney, New South WalesPrimary

Grid intelligence Members

Spending power

TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.

Spending power

Notify me about spending power

Signals & hiring

Hiring, headcount and registry-change signals, streamed to members.

Latest signal
Hiring activity
Headcount trend
Notify me about signals

Financials

Registry-filed capital and financial indicators, standardised by TheGrid.

Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
Notify me about financials

People & contacts

2 employee profiles on record · names withheld.

Counts only. No names are stored here, and none are served.

Notify me about contacts Tell us who you need to reach and we will tell you when a consented source is live.

FAQ

Which legal entity operates under NeuClone?

One New South Wales entity on the ABR. NEUCLONE PTY LTD (ABN 56 123 989 659), high confidence.

How many people work at NeuClone?

The record holds 9 counted staff profiles at January 2026. Its self-reported band sits above that count and is not published as a headcount.

Where does NeuClone have offices?

One address on record, Australia only. Primary: 4 Cornwallis St, Sydney, New South Wales.

Has NeuClone raised funding?

None linked to this brand.

What does NeuClone list as its specialties?

Five tags on the brand's own list, among them biosimilars, monoclonal antibodies and biosimilar antibody development in CHO cells.

Which companies are listed alongside NeuClone?

9 profiles list NeuClone as a peer — 83rd percentile in Pharmaceutical Manufacturing. It lists ten peers of its own.

What is NeuClone's website?

neuclone.com